Castle Biosciences, Inc. (CSTL)

In the past six months, Castle Biosciences reported strong Q2 2025 results, with revenue topping estimates and total test report volume increasing significantly year-over-year, leading management to raise its full-year 2025 revenue guidance. The company is scheduled to release its Q3 2025 financial results on November 3, 2025. Analyst ratings have generally been positive, with some firms issuing "Buy" or "Strong Buy" ratings and an average price target suggesting potential upside. The stock's year-to-date performance has seen a decline of 10.9% as of October 23, 2025. Insider trading activity during this period has shown more sales than purchases, with the President and CEO, Derek J. Maetzold, and Chief Operating Officer, Kristen M. Oelschlager, selling shares. The company has also announced its participation in upcoming investor conferences in November 2025, including the Stephens 27th Annual Investment Conference and the Jefferies Global Healthcare Conference.

Specific information regarding demand seasonality for Castle Biosciences' products and services is not explicitly detailed in the provided search results. However, the nature of molecular diagnostic tests for serious conditions like cancer and Barrett's esophagus suggests that demand is primarily driven by clinical need, disease incidence, and physician recommendations rather than significant seasonal fluctuations. The company has reported "strong clinical demand" for its diagnostics.

Castle Biosciences, Inc. is a molecular diagnostics company focused on improving health outcomes through innovative tests that guide patient care. The company specializes in developing and commercializing proprietary molecular diagnostic tests for various conditions, including dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health disorders. Its major products include DecisionDx-Melanoma, a gene expression profile (GEP) test that assesses the risk of metastasis in patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a GEP test that evaluates the risk of metastasis in patients with cutaneous squamous cell carcinoma; MyPath Melanoma and DiffDx-Melanoma, tests designed to help differentiate between benign and malignant skin lesions; TissueCypher Barrett's Esophagus Test, a spatial omics test that identifies patients at high risk of progression to esophageal cancer; DecisionDx-UM, a GEP test that provides prognostic information and predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that guides optimal drug treatment for patients diagnosed with various mental health conditions.

Castle Biosciences primarily conducts its operations within the United States. The company's corporate headquarters are located in Friendswood, Texas, and it maintains clinical laboratory operations in Phoenix, Arizona, and Pittsburgh, Pennsylvania. While the company has a limited international presence, it aims to expand into international markets.

Castle Biosciences has received positive recognition for its brand and leadership in the past year. The company was included in Newsweek's inaugural "America's Greatest Companies 2025" list and was honored as a "Greater Pittsburgh Top Workplace 2025" by The Pittsburgh Post-Gazette. Derek Maetzold, the company's founder, president, and chief executive officer, was named a "Most Admired CEO" by the Houston Business Journal in July 2025. In October 2025, new data demonstrating the effectiveness of its TissueCypher Barrett's Esophagus test in influencing clinical management earned a Presidential Poster Award at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting, enhancing the company's scientific reputation.

Institutional investors hold a significant portion of Castle Biosciences' stock, with institutional ownership reported at approximately 91.08% to 92.60%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Principal Financial Group Inc, Portolan Capital Management, LLC, Dimensional Fund Advisors Lp, Nuveen, LLC, Wasatch Advisors Inc, and Citadel Advisors Llc. Insider ownership is relatively low, around 2.48% to 7.20%. Retail and individual investors also hold a substantial portion of the company's stock.